These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 27096698)
21. Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: lipid clinic experience in 2 contrasting UK centres. Kohli M; Patel K; MacMahon Z; Ramachandran R; Crook MA; Reynolds TM; Wierzbicki AS Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28994502 [TBL] [Abstract][Full Text] [Related]
22. PCSK9 Inhibitors in Hyperlipidemia: Current Status and Clinical Outlook. Di Bartolo B; Scherer DJ; Brown A; Psaltis PJ; Nicholls SJ BioDrugs; 2017 Jun; 31(3):167-174. PubMed ID: 28424973 [TBL] [Abstract][Full Text] [Related]
23. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol. Ling H; Burns TL; Hilleman DE Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905 [TBL] [Abstract][Full Text] [Related]
24. Pleiotropic Effects of PCSK-9 Inhibitors. Basiak M; Kosowski M; Cyrnek M; Bułdak Ł; Maligłówka M; Machnik G; Okopień B Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33808697 [TBL] [Abstract][Full Text] [Related]
25. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602 [TBL] [Abstract][Full Text] [Related]
26. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy. Joseph L; Robinson JG Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence. Cicero AF; Tartagni E; Ertek S Expert Opin Biol Ther; 2014 Jun; 14(6):863-8. PubMed ID: 24661068 [TBL] [Abstract][Full Text] [Related]
28. PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: alirocumab. Dahagam C; Goud A; Abdelqader A; Hendrani A; Feinstein MJ; Qamar A; Joshi PH; Swiger KJ; Byrne K; Quispe R; Jones SR; Blumenthal RS; Martin SS Future Cardiol; 2016 Mar; 12(2):149-57. PubMed ID: 26911710 [TBL] [Abstract][Full Text] [Related]
29. Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data. Cicero AF; Tartagni E; Ertek S Expert Opin Drug Saf; 2014 Aug; 13(8):1023-30. PubMed ID: 24961142 [TBL] [Abstract][Full Text] [Related]
30. Significance of Monoclonal PCSK9-Antibodies - New Approaches to the Therapy of Hypercholesterolemia. Neumann CL; Schettler E; Schettler VJ Blood Purif; 2016; 41(4):270-6. PubMed ID: 26789774 [TBL] [Abstract][Full Text] [Related]
31. Alirocumab: A Review in Hypercholesterolemia. Greig SL; Deeks ED Am J Cardiovasc Drugs; 2016 Apr; 16(2):141-52. PubMed ID: 26935836 [TBL] [Abstract][Full Text] [Related]
32. Recent advance in lipid management: Focus on PCSK9I (Proprotein Convertase Subtilisin/ Kexin 9 Inhibitors). Kalra S J Pak Med Assoc; 2016 Sep; 66(9):1191-1193. PubMed ID: 27654746 [TBL] [Abstract][Full Text] [Related]
33. Atherosclerosis stabilization with PCSK-9 inhibition: An evolving concept for cardiovascular prevention. Robinson JG; Heistad DD; Fox KA Atherosclerosis; 2015 Dec; 243(2):593-7. PubMed ID: 26545013 [TBL] [Abstract][Full Text] [Related]
34. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. Lipinski MJ; Benedetto U; Escarcega RO; Biondi-Zoccai G; Lhermusier T; Baker NC; Torguson R; Brewer HB; Waksman R Eur Heart J; 2016 Feb; 37(6):536-45. PubMed ID: 26578202 [TBL] [Abstract][Full Text] [Related]
35. Effects of Hedan Tablet () on lipid profile, proprotein convertase subtilisin/kexin type 9 and high-density lipoprotein subfractions in patients with hyperlipidemia: A primary study. Xu RX; Wu NQ; Li S; Zhang Y; Li XL; Guo YL; Zhu CG; Liu G; Dong Q; Li JJ Chin J Integr Med; 2016 Sep; 22(9):660-5. PubMed ID: 25967607 [TBL] [Abstract][Full Text] [Related]
36. Profile of evolocumab and its potential in the treatment of hyperlipidemia. Cicero AF; Colletti A; Borghi C Drug Des Devel Ther; 2015; 9():3073-82. PubMed ID: 26109850 [TBL] [Abstract][Full Text] [Related]
37. A case of autosomal recessive hypercholesterolemia responsive to proprotein convertase subtilisin/kexin 9 inhibition. Fahy EF; McCarthy E; Steinhagen-Thiessen E; Vaughan CJ J Clin Lipidol; 2017; 11(1):287-288. PubMed ID: 28391897 [TBL] [Abstract][Full Text] [Related]
38. Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience. Gragnano F; Natale F; Concilio C; Fimiani F; Cesaro A; Sperlongano S; Crisci M; Limongelli G; Calabrò R; Russo M; Golia E; Calabrò P J Cardiovasc Med (Hagerstown); 2018 Feb; 19(2):75-77. PubMed ID: 29251697 [No Abstract] [Full Text] [Related]
39. The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications. Farnier M Am J Cardiovasc Drugs; 2011 Jun; 11(3):145-52. PubMed ID: 21619378 [TBL] [Abstract][Full Text] [Related]
40. Inhibition of pro-protein convertase subtilisin kexin 9 [corrected] (PCSK-9) as a treatment for hyperlipidaemia. Wierzbicki AS; Hardman TC; Viljoen A Expert Opin Investig Drugs; 2012 May; 21(5):667-76. PubMed ID: 22493980 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]